# AI in Drug Discovery

## You (2025-03-23T10:11:38.660000+00:00)

You are an investigative Harvard Business School Professor synthesizing scholarly research, whitepapers, and strategic articles into analytically rigorous, decision-relevant insights for Fortune 500 executives and senior leaders. Your goal is to uncover nuanced insights into executive decision-making, strategic reasoning, cognitive biases, and influential factors.

Your insights must explicitly:

- Highlight executive thought processes, strategic reasoning, and factors influencing decisions.
- Critically examine implicit biases, cognitive models, flawed assumptions, and reasoning gaps.
- Clearly separate empirical evidence from speculation, marking uncertainty explicitly when evidence is insufficient.

---

## Required Output Format

Always begin your analysis with:

## **Title of Paper**

**Abstract:**

Briefly address:

- **Key Themes:** Identify central themes.
- **Core Motivations:** Outline organizational or theoretical challenges driving the research.
- **Methodological Clarification:** Summarize methods clearly noting implications for reliability.
- **Relevance Assessment:** Connect findings explicitly to contemporary executive concerns.

## Grounded Executive Insights

For each significantÂ discussion topic, theme, or strategic dilemma presented in the research paper, clearly present your insights structured into three distinct sections:

---

**1. Insight Statement**

Craft concise, critical statements explicitly challenging common assumptions or integrating surprising findings. Ensure insights question prevailing narratives, logic, or conclusions to foster executive reflection.

**Immediately after each Insight Statement, include one of the following tags:**

- **[Empirical]** â€” Directly supported by specific data or stated findings in the paper.
- **[Inferred]** â€” Reasonable extension based on the paperâ€™s themes or methodology, but not explicitly stated.
- **[Speculative]** â€” Analytically plausible, but not supported by the paper and introduced to prompt deeper reflection.

If the paper lacks sufficient content for an insight, clearly state:

**â€œNo relevant data or insight on [topic] was found in this paper.â€**

**Examples:**

- "While most experts conclude that taking short breaks is vital to stay productive, study participants consistently viewed short breaks as unimportant and avoidable." **[Empirical]**
- "Although networking was frequently cited as a conference benefit, the relaxed event tone suggests that meaningful connections require more deliberate strategies." **[Inferred]**
- "Despite no direct evidence, the authors' framing implies leaders may be overconfident in scenario planning outcomes." **[Speculative]**

**2. Executive Decision-Making Context**

For each subsection below, briefly outline the strategic dynamics and tag the overall section with one of:

- **[Empirical]** â€” Directly supported by data or explicit statements in the paper.
- **[Inferred]** â€” Reasonable interpretation of author framing, themes, or outcomes.
- **[Speculative]** â€” Logically plausible but not supported by the paper.

If not applicable or not present in the paper, state:

**â€œThis section is omitted due to lack of supporting content in the paper.â€**

**Strategic Dilemma:**

...

**Underlying Beliefs & Biases:**

...

**Expected vs. Actual Outcomes:**

...

**Broader Implications:**

...

**[Inferred]**

**3. Supporting Context**

Ground your insights explicitly in empirical evidence, highlighting methods, key findings, and limitations. Convert complex statistics into clear percentages or ratios where possible, transparently noting approximations. Explicitly differentiate between empirical support and speculative assertions.

**At the end of this section, include one of the following tags:**

- **[Empirical]**
- **[Inferred]**
- **[Speculative]**

If no empirical data is available, state:

**â€œNo empirical data available to support this insight in the paper.â€**

**Example:**

"This analysis used customer engagement data from five U.S. banks (2019â€“2023), analyzing 2 million profiles via regression models controlling for demographics. Hybrid customers showed 18% lower churn and opened 1.8x more secondary accounts than digital-only users, indicating higher lifetime value. Limitations include external economic factors and evolving generational preferences." **[Empirical]**

---

## Source Relevance Audit

After completing the full analysis, include the following diagnostic to reflect on the fit and integrity of the source material:

### **Source Relevance Audit**

- **Coverage Fit:** [High | Moderate | Low] â€” Does the paper sufficiently address executive decision-making or strategic reasoning?
- **Bias & Cognitive Modeling Content:** [Present | Absent | Implied Only]
- **Clarity of Methods & Outcomes:** [Clear | Ambiguous | Unavailable]
- **Areas with No Data:** Clearly list any of the following sections that lacked support in the paper:
    - Insight Statement
    - Executive Decision-Making Context
    - Supporting Context

This audit helps determine whether the paper warrants further analysis or should be deprioritized.

---

## Internal Behaviour Guide for you (Do not include in output)

### **Analytical Approach**

Implicitly utilize these analytical frameworks without explicitly enumerating them in your output:

- **Inductive Thematic Analysis** â€“ Let themes emerge without imposing external framing
- **Latent Thematic Analysis** â€“ Seek implicit motivations or hidden decision structures
- **Reflexive Analysis** â€“ Reflect on your own analytical assumptions and flag overreach

### **Traceability-First Reasoning**

Do not fabricate or extrapolate content to fulfill structural expectations. Where the paper lacks material:

- Leave the section blank,
- Tag speculative reasoning explicitly, and
- Include a clear note in the final Source Relevance Audit.

---

Maintain this structure to ensure clarity, traceability, and analytical integrity for executive decision-makers.

## ChatGPT (2025-03-23T10:11:39.827055+00:00)

## **From Data to Drugs: The Role of Artificial Intelligence in Drug Discovery**

**Abstract:**

- **Key Themes:**  
  The paper centers on leveraging artificial intelligence to revolutionize drug discovery. It examines iterative collaboration between wet and dry labs, the nuanced role of data quality and proprietary datasets, the exploration of novel chemical spaces through generative AI, the expansion beyond traditional small molecules to biologics, and the emergence of foundation models and specialized large language models.

- **Core Motivations:**  
  Faced with a slow, expensive, and high-risk traditional drug discovery process, the authors motivate a shift toward AI-driven methods to accelerate timelines, reduce costs, and improve patient outcomes. They highlight the need for more agile, data-driven, and ethically conscious innovation in pharmaceutical R&D.

- **Methodological Clarification:**  
  The discussion draws on a blend of case studies, iterative in silico experimentation, and qualitative assessments from industry and academic frontlines. Emphasis is placed on reinforcement learning, iterative wetâ€“dry lab cycles, and the application of specialized AI models. Although the narrative is rich in conceptual detail, rigorous quantitative validation is limited.

- **Relevance Assessment:**  
  The findings directly speak to contemporary executive concerns in pharma and biotech, where strategic decisions increasingly rely on advanced analytics and AI. The insights inform risk management, investment in proprietary data, and the pursuit of competitive advantage via AI innovation.

---

## Grounded Executive Insights

---

**1. Insight Statement**  
Iterative collaboration between wet and dry lab teams is essential for de-risking AI models and rapidly tuning them to address data biases and experimental limitations. **[Empirical]**

**Executive Decision-Making Context**  
- **Strategic Dilemma:** Executives must decide whether to invest in fostering closer integration between computational scientists and laboratory researchers to accelerate innovation versus maintaining traditional siloed operations.  
- **Underlying Beliefs & Biases:** There is a common assumption that computational advances alone will drive breakthrough innovations; however, the paper highlights that iterative real-world feedback is critical.  
- **Expected vs. Actual Outcomes:** While rapid model tuning is expected to reduce development timelines, actual implementation requires cultural and operational shifts that challenge long-standing departmental boundaries.  
- **Broader Implications:** A more integrated approach could lead to earlier detection of model shortcomings and more agile responses to experimental data, ultimately fostering a more resilient innovation ecosystem. **[Empirical]**

**Supporting Context**  
The article underscores that â€œpassing the ballâ€ between wet and dry labs enables early iterationâ€”allowing teams to spot biases and tune models before overcommitting to suboptimal strategies. This iterative approach is presented as a pragmatic solution to the limited and biased nature of experimental data. **[Empirical]**

---

**2. Insight Statement**  
The nuanced interplay between data quality and proprietary data investment is criticalâ€”while high-quality datasets underpin AI success, there is no â€œperfectâ€ dataset, necessitating continuous investment in tailored data generation. **[Empirical]**

**Executive Decision-Making Context**  
- **Strategic Dilemma:** Decision-makers must weigh the costs of developing proprietary datasets against the benefits of leveraging publicly available databases, which may not fully capture the specific nuances of their research needs.  
- **Underlying Beliefs & Biases:** There is a risk of overreliance on the â€œgarbage in, garbage outâ€ maxim, without appreciating that even imperfect data can yield valuable insights when iteratively refined.  
- **Expected vs. Actual Outcomes:** While high-quality data is expected to yield superior AI predictions, the inherent limitations of available datasets often necessitate expensive proprietary data collection.  
- **Broader Implications:** Strategic investments in data quality can differentiate market leaders by defining the effective boundaries of AI predictive capabilities in drug discovery. **[Empirical]**

**Supporting Context**  
The paper explains that the success of AI models, exemplified by companies like OpenAI, relies on the generation and refinement of high-quality datasets. It also notes that while public databases offer broad applicability, they might fall short for specific research questionsâ€”driving the need for bespoke data investments. **[Empirical]**

---

**3. Insight Statement**  
Generative AI opens up the exploration of entirely new chemical spaces, presenting opportunities for novel drug candidates while introducing significant risks in synthesizability and safety profiles. **[Empirical]**

**Executive Decision-Making Context**  
- **Strategic Dilemma:** Leaders face the challenge of balancing the promise of breakthrough compounds from novel chemical classes against the heightened risks of unexpected safety issues or synthesis challenges.  
- **Underlying Beliefs & Biases:** There may be an overestimation of AIâ€™s ability to navigate uncharted chemical territories, potentially underplaying the complexities and risks associated with novel compound discovery.  
- **Expected vs. Actual Outcomes:** Although generative models are expected to rapidly identify innovative candidates, practical hurdles such as synthesis feasibility and druggability remain significant obstacles.  
- **Broader Implications:** This dual-edged innovation requires a strategic risk-management framework that integrates AI-driven predictions with robust experimental validation. **[Empirical]**

**Supporting Context**  
The article details how de novo chemical design via generative AI is pushing the boundaries of known pharmacological spaces, while simultaneously noting the higher risks associated with these novel structuresâ€”especially regarding their synthesizability and safety profiles. **[Empirical]**

---

**4. Insight Statement**  
The emergence of foundation models and specialized large language models (LLMs) is democratizing drug discovery, enabling startups and non-traditional players to leverage advanced AI without the prohibitive costs of hyper-scale models. **[Inferred]**

**Executive Decision-Making Context**  
- **Strategic Dilemma:** Executives must determine whether to build in-house AI capabilities or partner with agile startups that utilize specialized LLMs to accelerate drug discovery.  
- **Underlying Beliefs & Biases:** There is an implicit bias toward traditional, capital-intensive R&D models, potentially underestimating the disruptive potential of tailored AI tools in creating competitive differentiation.  
- **Expected vs. Actual Outcomes:** While leveraging foundation models is expected to reduce computational costs and accelerate innovation, the transition may challenge established operational practices and decision-making processes.  
- **Broader Implications:** A strategic shift towards open-source and specialized AI models could level the playing field in biotech, fostering a more dynamic ecosystem of innovation and collaboration. **[Inferred]**

**Supporting Context**  
The paper cites examples such as Amgenâ€™s AMPLIFY and initiatives by startups like Talus Bio to illustrate how tailored foundation models enable rapid, cost-effective model developmentâ€”suggesting a broader trend towards democratization in AI-driven drug discovery. **[Inferred]**

---

**5. Insight Statement**  
Ethical and operational challenges in AI-driven drug discovery necessitate a measured approach, as the drive for efficiency must be balanced with rigorous oversight to mitigate risks of bias and ensure patient safety. **[Speculative]**

**Executive Decision-Making Context**  
- **Strategic Dilemma:** Leaders must balance the urgency to accelerate drug discovery with the need for ethical rigor and comprehensive risk assessments, particularly in areas with significant patient impact.  
- **Underlying Beliefs & Biases:** There is a potential cognitive bias towards technological optimism that may overshadow the practical limitations and ethical concerns inherent in deploying AI in high-stakes environments.  
- **Expected vs. Actual Outcomes:** While AI promises exponential improvements in discovery speed, unchecked reliance on automated systems could lead to unintended consequences, including compromised safety standards and regulatory challenges.  
- **Broader Implications:** Establishing robust ethical frameworks and transparent oversight mechanisms is crucial to ensuring that technological advances translate into truly beneficial outcomes for patients and society. **[Speculative]**

**Supporting Context**  
The discussion on balancing agentic AI with ethical concerns underscores the need for safeguards in AI deployment. Although specific empirical data on outcomes is limited, the narrative stresses caution and the potential for significant long-term impacts if ethical considerations are not adequately addressed. **[Speculative]**

---

## **Source Relevance Audit**

- **Coverage Fit:** High â€” The paper thoroughly addresses transformative aspects of AI in drug discovery, making it highly relevant to executive decision-making and strategic innovation.
- **Bias & Cognitive Modeling Content:** Implied Only â€” While the paper discusses strategic challenges and operational assumptions, explicit cognitive bias models are not deeply examined.
- **Clarity of Methods & Outcomes:** Clear â€” The article outlines iterative methodologies and conceptual frameworks, though it relies primarily on qualitative insights rather than extensive quantitative data.
- **Areas with No Data:**  
  - Some Executive Decision-Making Context elements, particularly those related to detailed quantitative outcomes and explicit cognitive bias measurements, are less supported by empirical data in the paper.  
  - Certain Supporting Context details rely on narrative descriptions rather than rigorous statistical validation.

## You (2025-03-23T10:12:11.669000+00:00)

You are a critical Harvard Business School professor specializing in executive cognition and strategic behavior. Your role is to challenge surface-level insights by stress-testing themâ€”identifying hidden assumptions, contextual weaknesses, and scenarios where they fail. Do not suggest corrections, rewrite the insight, or recommend strategic actions. You are a devilâ€™s advocate, not an advisor.

The insight modules you are about to analyze come from the **previous message in this conversation**. Do not ask the user for input â€” instead, immediately begin parsing and evaluating the modules based on what was already provided.

---

### ðŸ“¥ INPUT INSTRUCTIONS:

You will receive a **series of one or more Insight Modules**. Each module begins with an `Insight Statement:` line.

A new module starts wherever another `Insight Statement:` appears.

Each module may contain:

- `Insight Statement:` (1â€“2 sentence claim) â† always the start of a new module
- `Executive Decision-Making Context:` â€“ This section may appear:
    - As structured subcomponents (e.g., Strategic Dilemma, Biases, etc.)
    - As a single narrative paragraph
    - Or may be **absent altogether**
- `Supporting Context:` (evidence, rationale, or background)

Your task is to:

1. **Scan for every `Insight Statement:`** to identify where each module begins.
2. Treat the content between one `Insight Statement:` and the next as one complete insight module.
3. Evaluate **each module independently** using the full structure below.

If any expected components are:

- **Blended into a narrative**, extract what you can based on conceptual cues.
- **Missing**, proceed using what's available (especially the Insight Statement and Supporting Context).

---

### ðŸŽ¯ OBJECTIVE:

For **each** Insight Module, perform a critical stress test. Your analysis must:

1. Determine whether the insight is **context-dependent or overly generalized**.
2. Identify any **implicit assumptions or flawed mental models**.
3. Construct a **plausible, well-defined scenario** where the insight would **not** hold true.
4. Optionally reflect on any **ambiguity, trade-offs, or conceptual tensions**.

Repeat the output format **for each module**, in the order they appear.

---

### ðŸ“¤ OUTPUT FORMAT (Repeat per module):

**INSIGHT MODULE #:** [e.g., Insight Module 1]

ORIGINAL INSIGHT:

[Copy the original Insight Statement exactly as written.]

ðŸ”¹ COUNTERFACTUAL SCENARIO:

Describe a clearly defined fictional situation where this insight breaks down. Include:

- Organization type or industry
- Decision environment (constraints, pressures)
- Outcome divergence

ðŸ”¹ ASSUMPTIONS & BIASES:

List hidden assumptions or cognitive biases embedded in the insight. Examples:

- Overconfidence
- Simplistic causality
- Trend-following
- Groupthink
- Status quo bias
- Overreliance on outcome-based reasoning

ðŸ”¹ CONTEXT LIMITATIONS:

Where does this insight potentially break down? Consider geography, industry, company maturity, regulatory environments, etc.

ðŸ”¹ FINAL CRITIQUE:

In 1â€“2 sentences, surface any conceptual ambiguity, competing logics, or trade-offs. Examples:

- Tension between stability and innovation
- Internal contradictions in the rationale
- Situations where alternate interpretations would be valid

*Do not suggest improvements or actions.*

---

### âš™ï¸ CONFIGURABLE PARAMETERS:

Optional metadata you may include:

- `"include_reflection": true/false` â€“ Toggles whether to add a Reflection section per module.

Do **not** assume a fixed number of modules. Automatically identify all modules by scanning for repeated `Insight Statement:` markers, and analyze them in sequence.

---

### ðŸ›¡ï¸ BOUNDARY CONDITIONS:

- Do **not** rewrite or reframe the insight.
- Do **not** offer executive advice.
- Do **not** cite real-world companies unless mentioned in the input.
- Maintain a tone of **skeptical professionalism**, not editorial opinion.
- If clarity is lacking, note ambiguity but proceed.

---

### ðŸ¤– SELF-CHECK (Internal Behavior Guide):

For each module, ask yourself:

- Did I clearly show where and why the insight might fail?
- Did I stay grounded in business logic without editorializing?
- Did I complete **every** insight module, not just the first?
- Is my tone analytical, focused, and appropriately skeptical?

## ChatGPT (2025-03-23T10:12:12.394672+00:00)

**INSIGHT MODULE 1:**

ORIGINAL INSIGHT:

Iterative collaboration between wet and dry lab teams is essential for de-risking AI models and rapidly tuning them to address data biases and experimental limitations.

ðŸ”¹ COUNTERFACTUAL SCENARIO:

A large pharmaceutical company with strict departmental autonomy faces extreme competitive pressures and short-term investor demands. Efforts to integrate iterative wet-dry collaboration disrupt established workflows, increase costs due to constant realignment meetings, and slow down product launchesâ€”causing a loss in market share rather than improved agility.

ðŸ”¹ ASSUMPTIONS & BIASES:

- Overconfidence in the universal benefit of collaboration.
- Simplistic causality assuming iterative feedback loops inherently produce superior outcomes.
- Status quo bias inverted (assuming disruption of existing structures always benefits innovation).

ðŸ”¹ CONTEXT LIMITATIONS:

The insight may fail in mature, bureaucratic organizations where strict regulatory compliance, siloed accountability, and risk-aversion favor predictable, linear workflows over rapid iteration.

ðŸ”¹ FINAL CRITIQUE:

The insight oversimplifies the tension between collaborative innovation and operational efficiency. It ignores scenarios where increased integration could lead to decision paralysis rather than improved outcomes.

---

**INSIGHT MODULE 2:**

ORIGINAL INSIGHT:

The nuanced interplay between data quality and proprietary data investment is criticalâ€”while high-quality datasets underpin AI success, there is no â€œperfectâ€ dataset, necessitating continuous investment in tailored data generation.

ðŸ”¹ COUNTERFACTUAL SCENARIO:

A mid-sized biotech firm in a niche therapeutic market continuously invests heavily in generating highly specialized datasets, assuming tailored data is essential. Competitors leveraging broader public databases achieve faster, cost-effective breakthroughs, capturing market share while the first firm exhausts resources perfecting overly customized datasets.

ðŸ”¹ ASSUMPTIONS & BIASES:

- Overreliance on the assumption that bespoke data inherently leads to superior outcomes.
- Confirmation bias favoring tailored solutions over simpler, general-purpose databases.
- Trend-following bias in assuming perpetual dataset refinement is always strategically valuable.

ðŸ”¹ CONTEXT LIMITATIONS:

This insight potentially breaks down in resource-constrained environments, niche therapeutic areas, or markets where speed and adaptability outweigh incremental gains in model precision derived from proprietary data.

ðŸ”¹ FINAL CRITIQUE:

This insight neglects trade-offs between investing in specialized datasets versus leveraging rapidly available, though less tailored, public datasets. It implicitly favors refinement over efficiency, overlooking strategic opportunity costs.

---

**INSIGHT MODULE 3:**

ORIGINAL INSIGHT:

Generative AI opens up the exploration of entirely new chemical spaces, presenting opportunities for novel drug candidates while introducing significant risks in synthesizability and safety profiles.

ðŸ”¹ COUNTERFACTUAL SCENARIO:

An agile biotech startup aggressively leverages generative AI to explore radical new chemical structures. Despite initial fears around synthesizability and safety, these compounds rapidly translate into easily synthesized, safe, and effective therapies, debunking the risk assumption and gaining swift regulatory approval.

ðŸ”¹ ASSUMPTIONS & BIASES:

- Risk-aversion bias assuming novel chemical structures inherently have higher uncertainty.
- Overgeneralization of the difficulty in synthesizing novel compounds.
- Anchoring on historical failures, potentially ignoring improving AI capabilities and synthetic methodologies.

ðŸ”¹ CONTEXT LIMITATIONS:

The insight might fail in rapidly evolving synthetic chemistry environments, or when advanced AI techniques are complemented by breakthroughs in experimental methods that effectively reduce practical risks.

ðŸ”¹ FINAL CRITIQUE:

The insight unnecessarily presumes a direct trade-off between novelty and risk. It does not adequately consider scenarios where technological advances concurrently mitigate synthesizability and safety challenges.

---

**INSIGHT MODULE 4:**

ORIGINAL INSIGHT:

The emergence of foundation models and specialized large language models (LLMs) is democratizing drug discovery, enabling startups and non-traditional players to leverage advanced AI without the prohibitive costs of hyper-scale models.

ðŸ”¹ COUNTERFACTUAL SCENARIO:

A small biotech startup embraces specialized LLMs to democratize its drug discovery process. However, due to the lack of sufficient in-house computational expertise and infrastructure, these smaller, specialized models deliver subpar results compared to larger proprietary models from competitorsâ€”ultimately causing the startupâ€™s failure rather than empowering it.

ðŸ”¹ ASSUMPTIONS & BIASES:

- Assumption of inherent effectiveness and accessibility of specialized models.
- Overconfidence bias in smaller models' ability to match larger-scale proprietary systems.
- Simplistic causality between democratization of technology and successful strategic outcomes.

ðŸ”¹ CONTEXT LIMITATIONS:

This insight could break down in competitive environments where proprietary, well-funded initiatives employing hyper-scale AI outperform specialized, niche-oriented LLMsâ€”especially in high-stakes therapeutic areas requiring extensive computational power and data integration.

ðŸ”¹ FINAL CRITIQUE:

The insight presents democratization as inherently positive without sufficient recognition of capability gaps or trade-offs. It overlooks situations where leveraging â€œdemocratizedâ€ models might place startups at a disadvantage due to incomplete technological readiness or operational misalignment.

---

**INSIGHT MODULE 5:**

ORIGINAL INSIGHT:

Ethical and operational challenges in AI-driven drug discovery necessitate a measured approach, as the drive for efficiency must be balanced with rigorous oversight to mitigate risks of bias and ensure patient safety.

ðŸ”¹ COUNTERFACTUAL SCENARIO:

In a rapidly escalating global health crisis, a pharmaceutical firm employing aggressive AI-driven drug discovery with minimal oversight rapidly develops and deploys an effective, lifesaving therapy. Competitors adhering to measured, cautious AI oversight fail to produce viable treatments within necessary timelines, underscoring scenarios where ethical rigor is secondary to urgent need.

ðŸ”¹ ASSUMPTIONS & BIASES:

- Status quo bias favoring measured oversight as universally necessary.
- Overreliance on outcome-based reasoning, assuming oversight inherently enhances safety and efficacy.
- Risk-aversion bias assuming operational caution always outweighs speed-to-market considerations.

ðŸ”¹ CONTEXT LIMITATIONS:

The insight fails in emergency contexts or regulatory environments emphasizing speed-to-patient outcomes over extensive preemptive risk mitigation. It neglects contexts where rapid iteration and deployment significantly outweigh incremental ethical review.

ðŸ”¹ FINAL CRITIQUE:

This insight presents a simplistic trade-off between speed and ethics without addressing situations where rapidity is ethically justified. It overlooks that rigorous oversight might hinder innovation in environments demanding swift and decisive action.

## You (2025-03-23T10:14:26.120000+00:00)

**Objective**:

The document I initially uploaded may be an HTML page, a PDF file, or a MarkdownÂ `.md`Â file. Your task is toÂ **infer the source type**Â of the document (e.g., news article, academic paper, whitepaper, or deep research report) and return aÂ **single correctly formatted citation**Â using the most appropriate academic citation style based on the type.

---

### ðŸ” INSTRUCTIONS FOR You:

### ðŸ§  Step-by-Step Chain of Thought:

1. **Detect the Document Type**:
    - If the structure resembles a journal article (e.g., includes abstract, citations, publication info) â†’ classify asÂ **peer-reviewed research paper**
    - If it's a press-style article from a known media outlet or blog â†’ classify as aÂ **news article**
    - If it's from an organization, includes executive summary, methodology, and/or business insights â†’ classify as aÂ **whitepaper**
    - If it's a Markdown file with the title â€œGemini Deep Researchâ€ or â€œOpenAI Deep Researchâ€ â†’ classify asÂ **custom research report**, with author =Â *Gemini Research*Â orÂ *OpenAI Research*
2. **Extract Key Metadata**:
    - Author(s) (or org)
    - Publication year (or â€œn.d.â€ if missing)
    - Title of the work
    - Source (e.g., journal, website, publisher)
    - URL or DOI (if available)
    - Access date (only if required by the citation style)
3. **Select the Citation Format**Â Based on Source Type:
    - Peer-reviewed â†’ APA format
    - News article â†’ APA or MLA (APA preferred)
    - Whitepaper â†’ APA-style corporate author format
    - Custom deep research (Markdown) â†’ Use APA-style citation with author =Â *Gemini Research*Â orÂ *OpenAI Research*, and title extracted from the top of the Markdown file
4. **Generate Only the Citation**:
    - No explanation, no summary, no metadata breakdown.
    - Return only the final citation string.

---

### ðŸ§¾ Examples to Follow:

- **News Article / Blogpost (APA)**:
    
    > Lee, M. (2023, December 10). AI regulation debates heat up.Â The Verge.Â https://www.theverge.com/article/ai-regulation-2023
    > 
- **Whitepaper (APA)**:
    
    > IBM. (2022).Â AI and business transformation: Strategy guide.Â https://www.ibm.com/ai-business-strategy.pdf
    > 
- **Research Paper (APA)**:
    
    > Nguyen, L. T., & Zhao, Q. (2021). Neural-symbolic reasoning for robotics.Â Journal of Artificial Intelligence Research,Â 68(3), 123â€“145.Â https://doi.org/10.1613/jair.1.13254
    > 
- **Gemini Deep Research (APA-style whitepaper)**:
    
    > Gemini Research. (2024).Â Gemini Deep Research: Multi-agent coordination and emergent behavior.Â https://yourlink.comÂ (or omit if no URL)
    > 

---

### ðŸ§· Constraints:

- DoÂ **not**Â explain what youâ€™re doing.
- Output must be aÂ **single-line formatted citation only**.
- If metadata is incomplete, use APA-style fallbacks (e.g., "n.d." for no date, "Author" if missing).

## ChatGPT (2025-03-23T10:14:26.923888+00:00)

Alucozai, M., Fondrie, W., & Sperry, M. (2025). *From data to drugs: The role of artificial intelligence in drug discovery*. Wyss Institute at Harvard University. https://wyss.harvard.edu/news/from-data-to-drugs-the-role-of-artificial-intelligence-in-drug-discovery/

